Retrospective Study Evaluating the Management of Psychotic Disorders at Behavioral Medicine Dept - SQUH

Dr. Amr Guenedi; Dr. Yousif Obeid

Authors

Dr. Amr Guenedi
Dr. Yousif Obeid

Keywords:

Abstract

Introduction-Hundreds of millions of people worldwide are affected by mental, behavioral, neurological and substance abuse disorders. For example, estimates made by WHO in 2002 showed that 154 million people globally suffer from depression and 25 million people from schizophrenia. (1) This exerts tremendous social, medical and financial burden. Early intervention and effective management can easily reduce this burden significantly. One other main disorders encountered and constitute real challenge are the psychotic disorders. They constitute 3 to 4 % of all mental disorders (1). They have gained special interest due to its possible chronic course and hence its long term economic and social impact. Cost-effective treatments exist for most disorders and, if correctly applied, could enable most of those affected to become functioning members of society.

Downloads

How to Cite

Retrospective Study Evaluating the Management of Psychotic Disorders at Behavioral Medicine Dept - SQUH. (2014). Global Journal of Medical Research, 14(9), 11-14. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

(2008) World health organization, official site: who. 32-44. https://doi.org/10.4324/9780203029732-9

Boronow J (2001) Boronow J (Psychiatr Serv. 52, 1299-1305.

DSM IV.

D. Casey (1996) Side effect profiles of new antipsychotic agents. 11, 40-45.

H. Meltzer, H. Fibiger (1996) Olanzapine: a new typical antipsychotic drug. 14(2), 83-85.

Olanzapine (1997) Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. 53(2), 281-98.

V. Patrick, E. Levin, S. Schleifer (2005) Antipsychotic Polypharmacy: Is There Evidence for its Use?. 11(4), 248-257.

John Newcomer (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. 19(Supplement 1), 1???93. https://doi.org/10.2165/00023210-200519001-00001

M. Lambert, P. Conus, B. Schimmelmann, P. Eide, J. Ward, H. Yuen, M. Schacht, J. Edwards, D. Naber, P. Mcgorry (2005) Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study. 38(5), 206-13.

J. Kraus, B. Sheitman, A. Cook, R. Reviere, J. Lieberman (2005) Olanzapine Versus Risperidone in Newly Admitted Acutely Ill Psychotic Patients. 66(12), 1564-1568.

R. Carnahan, B. Lund, P. Perry, E. Chrischilles (2006) Increased risk of extrapyramidal side‐effect treatment associated with atypical antipsychotic polytherapy. 113(2), 135-141.

risperidone (2006) A Practical Clinical Trial Comparing Haloperidol, Risperidone, and Olanzapine for the Acute Treatment of First-Episode Nonaffective Psychosis. 67(10), 1511-1521.

Comparative antipsychotics, haloperidol schizophrenia (2006) Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. 189, 433-440.

Muller Selecting patients for long-acting novel antipsychotic therapy.

I. Schweitzer (2001) Does risperidone have a place in the treatment of nonschizophrenic patients?. 16, 1-19.

S. Stahl Stahl S: Essential pharmacology of antipsychotics and mood stabilizers. 2.

S. Stahl (2002) Stahl S: Psychopharmacologie essentielle - 2002.

S. Stahl (2006) Stahl S: The prescriber's guide: antipsychotics and mood stabilizers.

Stephen Stahl (2009) Essentials of psychopharmacology.

Amen D: Functional neuroanatomy. http://www.a-menclinics.com